EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells

BACKGROUND: BRAF inhibitor (BRAF-I) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms behind BRAF-I responsiveness and acquired resistance is therefore an important iss...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EBioMedicine
Glavni autori: Laurenzana, Anna, Margheri, Francesca, Biagioni, Alessio, Chillà, Anastasia, Pimpinelli, Nicola, Ruzzolini, Jessica, Peppicelli, Silvia, Andreucci, Elena, Calorini, Lido, Serratì, Simona, Del Rosso, Mario, Fibbi, Gabriella
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2019
Teme:
Research paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355443/
https://ncbi.nlm.nih.gov/pubmed/30611716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2018.12.024
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items